Pharvaris (NASDAQ:PHVS) Sees Large Volume Increase – Time to Buy?

Pharvaris (NASDAQ:PHVS) saw an uptick in trading volume on Wednesday . 112,320 shares traded hands during trading, an increase of 27% from the previous session’s volume of 88,353 shares.The stock last traded at $18.08 and had previously closed at $17.90.

Analyst Ratings Changes

Separately, Oppenheimer lifted their price target on shares of Pharvaris from $38.00 to $42.00 and gave the company an “outperform” rating in a report on Friday, September 6th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.60.

Pharvaris Stock Down 1.1 %

The business has a 50 day moving average of $18.44 and a 200 day moving average of $19.36. The company has a market capitalization of $563.57 million, a P/E ratio of -6.68 and a beta of -3.10.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Wednesday, August 14th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). On average, research analysts anticipate that Pharvaris will post -2.58 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. venBio Partners LLC lifted its stake in shares of Pharvaris by 15.4% in the 4th quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock valued at $137,992,000 after purchasing an additional 654,832 shares during the last quarter. Novo Holdings A S lifted its position in Pharvaris by 47.7% in the second quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock worth $32,430,000 after buying an additional 556,970 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its stake in Pharvaris by 31.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock worth $26,269,000 after buying an additional 335,687 shares during the period. Commodore Capital LP bought a new position in Pharvaris during the fourth quarter valued at $22,440,000. Finally, Sofinnova Investments Inc. raised its stake in shares of Pharvaris by 2.9% in the second quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock valued at $11,309,000 after acquiring an additional 16,862 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.